Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

ANNAPOLIS, Md., April 28 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conference on Vaccine Research, being held in Baltimore, MD, April 27-29, 2009. The conference is sponsored by the National Foundation of Infectious Diseases.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "We are very pleased to have had the opportunity to present these latest data for SparVax(TM) at Annual Conference on Vaccine Research. The study, which compared our vaccine to the currently licensed anthrax vaccine, BioThrax(R), provides further confirmation that SparVax(TM) is immunogenic and promotes good immunological recall following antigenic challenge. In addition, a lower incidence of injection site reactions observed with SparVax(TM) may suggest that it is better tolerated than BioThrax(R), a very important finding for this product candidate. Presentation of these data to attendees at this conference allows PharmAthene to continue to increase awareness of the progress we are making developing improved products using modern vaccine technologies to protect our Nation's citizens and military."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene.

The study was one of two Phase II trials evaluating different dose and dosing regimens of Sp
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Biomedical Research Program Awards Peer-Reviewed Grant, SARASOTA, Fla., ... was awarded the Florida Department of Health and James ... for its advanced cancer research in using B-amyloid protein ... in the amount of $100,000 was awarded to Roskamp,s,Investigator ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... a challenge of the patents listed by TAP,Pharmaceuticals ... Disintegrating Tablets (lansoprazole), 15mg and,30mg., Barr filed ... IV certification for a generic Prevacid SoluTab product ...
... Va., June 10 Diffusion Pharmaceuticals,LLC, a clinical-stage ... life-threatening unmet medical needs, today announced,the addition of ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080610/NETU101 ), Mr. ... Virginia National Bank in,Charlottesville, Virginia. He also is ...
Cached Biology Technology:Roskamp Institute Wins Grant for Lung Cancer Research 2Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg 2Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg 3Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors 2
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming the travel ... international borders. Over the past decade, ePassports, biometric readers, ... self process through border control via eGates and Automated ... airports, seaports, and land borders across the globe. ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... often behave differently than temperate soils when being farmed. ... cultivated. With food shortages looming and soil quality declining ... and sub-tropical farming more productive and sustainable. New research ... a winter cover crop is most effective in retaining ...
... Georgia researchers have developed a new technology that ... from readily available non-food crops, such as Bermudagrass, ... "Producing ethanol from renewable biomass sources such as ... in large quantities," said Joy Peterson, professor of ...
... the U.S. will be overweight or obese by 2030, with ... $956.9 billion, according to researchers at the Johns Hopkins Bloomberg ... Quality and the University of Pennsylvania School of Medicine. Their ... Obesity . "National survey data show that the ...
Cached Biology News:New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 2New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 3Study suggests 86 percent of Americans could be overweight or obese by 2030 2
Human SPARC-like 1 Biotinylated Affinity Purified PAb...
Request Info...
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Request Info...
Biology Products: